23.09.2019phenox Announces Exclusive Distribution Agreement with Wallaby Medical Inc. for The Avenir™ Coil System in The United States and Europe

phenox is pleased to announce that it has signed an exclusive distribution agreement with Wallaby Medical Inc. for commercialization of The Avenir™ Detachable Coil System in the U.S. and EU markets.  The intended use for the Avenir Coil System is for endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae. The Avenir Coil System is also intended for arterial and venous embolization in the peripheral vasculature.

“The Avenir Coil is highly complementary to our existing portfolio of neurovascular technologies, and we are looking forward to our commercial partners

23.09.2019phenox employee Diana Stateczny wins European Championship in Snooker

Named the queen of Belgrade by EBSA.tv, Diana Stateczny became Europe’s 2019 snooker champion. Her 24 years of training at the table with a decade dedicated to snooker paid off.

Her victory is impressive. She doesn’t train like the others, she works full time on top of training. To a certain extent, she admits her work is part of her training and it contributed to make her the person she is today: down to earth, focused and dynamic. 

“When I go play snooker after a working day behind the microscope, I have learned how to stay present, focused, and work on my endurance. My job also helped me become a more f

15.05.2018phenox GmbH wins project and receives extensive funding

The „AntiThromb“ project is announced to be the winner of the KMU-NetC competition of the Federal Ministry of Education and Researsch and therefore receives an enormous funding out of federal resources. The goal of the phenox project is to develop a path-breaking coating, which imitates the natural vessel wall, to be used on implants for the treatment of cerebral aneurysms. The use of such a coating it would make it possible to reduce lifelong medication which still is the current standard.

Such a medication is necessary to prevent the formation of a thrombus caused by the use of implants in the cerebral artery and therefore presents the standardi

14.05.2018phenox GmbH participates in „Girls Day“

The „Girls and Boys Day“ takes place once a year throughout the whole nation. Its goal is to set off traditional role models by showing young students careers that are considered „typical“ for the other gender. Thus, many young boys spend the day in i.e. Kindergarden, to get to know the occupation of an educator. Girls on the other side get to know those occupations, where male employees make up the bigger part of the staff. Those are jobs in the IT-sector, work on a construction site or

19.03.2018Member of European Parliament Dennis Radtke visits phenox GmbH

The CDU deputy and member of the European Parliament Dennis Radtke visited phenox GmbH at its headquarter in Bochum on the 12th of February, 2018. The politician, who is originally from the Ruhr area, came to observe the great challenges which medical technology companies such as phenox GmbH located in Bochum must face today. Especially for medium-sized companies, the new EU-Medical-Device-Regulation implies an increased effort in documentation and enlarged appro

10.07.2017phenox as Silver Sponsor of LINNC 2017

On June 13-15, the 20thLive International Neuroradiology and Neurosurgery Course” took place. Specialists of neuroradiology met at the Carrousel du Louvre in Paris, to discuss live cases which were presented from all over the world. phenox has sponsored the LINNC for years. This year was the first time phenox was a silver sponsor of the meeting and was present with a booth, a training area as well as its own symposium.

The discussion on treatment of bifurcation aneurysms was titled “How to Decide? Bifurcation Aneurysm Treatment Options”, and moderated by Dr. Saleh Lamin from Birmingham, Great Britain

18.05.2017Phenox as partner of WLNC - World Live Neurovascular Conference in Los Angeles


This Year, phenox again acts as a sponsor for the 5th WLNC – World Live Neurovascular Conference, one of the most important conferences in the field of stroke therapy. The congress, which was held from 15 until 18 May in Los Angeles, CA, US, addressing neuroradiologists, neurosurgeons and neurologists all over the world. One of the main topics is the treatment of neurovascular strokes – a field in which phenox is one of the international leading companies. Every year the WLNC is hosted in different cities to highlight its internation

04.04.2017Congratulations - Our Dual Students made it!

With a festive ceremony the first two trainees of the dual curriculum finished their education as precision engineering technicians. Since 2015 the phenox GmbH offers the dual curriculum Physical Technology with fine mechanics as its core area (Bachelor of Science). This degree is made possible through the cooperation with GAEDIGK Feinmechanik & Systemtechnik GmbH, Westfälische Hochschule Gelsenkirchen and Handwerkskammer Dortmund. Lisa Gräbnitz and Peter Böker received their apprenticeship diploma on April 1st of 2017. The educational part at phenox GmbH is therefore done for our trainees.

03.11.2016phenox pREset Thrombectomy Device proves to be safe and effective

The treatment of mechanical thrombectomy represents a highly effective therapy in patients with acute ischemic stroke. This was recently proven by four randomized controlled trials (MR CLEAN1, SWIFT-PRIME2, EXTEND-IA3, ESCAPE4), in patients with a proximal large vessel occlusion. The ARTESp study, recently published by Dr. Sascha Prothmann, Department of Diagnostic and Interventional Neuroradiology at Klinikum rechts der Isar, et al., mirrors and reinforces the findings of the above mentioned trials.

ARTESp (Acute Recanalization of Thrombo-Embolic Ischemic Stroke with pREset®) is a prospective, multicenter, single-arm Post Market Clinical Fo

07.03.2016SITS Open stroke trial includes pREset Thrombectomy Device by phenox GmbH


phenox GmbH, announces participation in the SITS Open clinical trial where pREset and pREset LITE Thrombectomy Devices have been included in the study device portfolio, one of only three devices to be used in the study.

Stroke is the second leading cause of death worldwide and the most common cause of adult disability in the western world. Ischemic stroke, caused by a blocked artery, is the most common type of stroke and it takes only minutes without oxygen for brain damage to occur and more brain cells die every minute that flow is blocked. The aim of physicians is to restore blood flow by opening the bloc

11.08.2015phenox project wins lead market competition

The project “FilaMem” is the winner of the lead market competition “NeueWerkstoffe.NRW” (New Materials North Rhine-Westphalia) and has therefore been nominated by the state government for a huge sponsorship combining state and EU funding. The development of biofunctional hybrid membranes for long-term implant materials is supposed to be realized in this project. In addition to phenox, the company femtos (located in Bochum as well), PS Materials (based in Aachen) and the medical faculty of RWTH Aachen University participate in the project’s implementation. 

The aim of “FilaMem” is to develop new stents for the treatment of strokes. In order to be able to t

17.06.201510th anniversary of phenox

On the occasion of phenox’s 10th anniversary, a big celebration was held on June 12 on phenox’s premises. Around 150 employees and their family members attended the festivities which were accompanied by fine weather. Managing Partners Dr.-Ing. Hermann Monstadt and Ralf Hannes congratulated their colleagues who have been working with them for 10 years by presenting them with awards.

One week earlier, the Ruhr University Bochum (RUB) equally celebrated its anniversary which was called “BlauPause”: 2015 marks the 50th

16.10.2014phenox symposium at NeuroRAD 2014

As in recent years, the phenox GmbH is taking part in the annual meeting of the DGNR held from the 23rd to 25th October 2014 in Cologne. We cordially invite all participants to this year's symposium.
"Treatment of complex aneurysms with new phenox products"
Where: Cologne, Gürzenich
When: Friday, 24th October 2014, 3.15 pm

Prof. Dr. Arnd Dörfler, Head of the Department of Neuroradiology, Universitätsklinikum Erlangen

pREset LT - first experiences
Dr. Wiebke Kurre
Senior Physician,
Klinik für Diagnostische und Interventi

no news in this list.